234 related articles for article (PubMed ID: 11334895)
1. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.
Mulders TM; Dieben TO
Fertil Steril; 2001 May; 75(5):865-70. PubMed ID: 11334895
[TBL] [Abstract][Full Text] [Related]
2. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
3. Complete and robust ovulation inhibition with NuvaRing.
Killick S
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():13-8; discussion 37-9. PubMed ID: 12659397
[TBL] [Abstract][Full Text] [Related]
4. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
[TBL] [Abstract][Full Text] [Related]
5. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
Seidman L; Kroll R; Howard B; Ricciotti N; Hsieh J; Weiss H
Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
[TBL] [Abstract][Full Text] [Related]
6. Ovarian function during low-dose oral contraceptive use.
Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.
Timmer CJ; Mulders TM
Clin Pharmacokinet; 2000 Sep; 39(3):233-42. PubMed ID: 11020137
[TBL] [Abstract][Full Text] [Related]
8. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
van Heusden AM; Fauser BC
Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
[TBL] [Abstract][Full Text] [Related]
9. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity.
Sullivan H; Furniss H; Spona J; Elstein M
Fertil Steril; 1999 Jul; 72(1):115-20. PubMed ID: 10428158
[TBL] [Abstract][Full Text] [Related]
10. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
[TBL] [Abstract][Full Text] [Related]
11. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.
Pierson RA; Archer DF; Moreau M; Shangold GA; Fisher AC; Creasy GW
Fertil Steril; 2003 Jul; 80(1):34-42. PubMed ID: 12849799
[TBL] [Abstract][Full Text] [Related]
12. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
Elomaa K; Lähteenmäki P
Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
[TBL] [Abstract][Full Text] [Related]
13. Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing.
Duijkers I; Klipping C; Heger-Mahn D; Fayad GN; Frenkl TL; Cruz SM; Korver T
Eur J Contracept Reprod Health Care; 2018 Aug; 23(4):245-254. PubMed ID: 30203681
[TBL] [Abstract][Full Text] [Related]
14. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
[TBL] [Abstract][Full Text] [Related]
15. Follicular growth during contraceptive pill or vaginal ring treatment depends on the day of ovulation in the pretreatment cycle.
Duijkers IJ; Verhoeven CH; Dieben TO; Klipping C
Hum Reprod; 2004 Nov; 19(11):2674-9. PubMed ID: 15319379
[TBL] [Abstract][Full Text] [Related]
16. Lower hormone dosage with improved cycle control.
Vree M
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():25-30; discussion 37-9. PubMed ID: 12659399
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
18. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
Roumen FJ; Dieben TO
Fertil Steril; 2006 Jan; 85(1):57-62. PubMed ID: 16412731
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
Fan GS; Ren M; Di W; Su P; Chang Q; Wu S; Qin Y; Korver T; Marintcheva-Petrova M; Yacik C; McCrary Sisk C; Wang G
Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):303-9. PubMed ID: 27339759
[TBL] [Abstract][Full Text] [Related]
20. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
Archer DF; Kovalevsky G; Ballagh SA; Grubb GS
Contraception; 2009 Sep; 80(3):245-53. PubMed ID: 19698816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
